SCHEMBL1134058

SCHEMBL1134058

O=COC1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 6/20 0.60
AKR1C3 P42330 5/20 0.60
AKR1C2 P52895 5/20 0.60
CYP2C19 P33261 4/20 0.60
CYP3A4 P08684 4/20 0.60
CYP2C9 P11712 3/20 0.60
PSEN1 P49768 2/20 0.60
PSEN2 P49810 2/20 0.60
APH1B Q8WW43 2/20 0.60
NCSTN Q92542 2/20 0.60
APH1A Q96BI3 2/20 0.60
PSENEN Q9NZ42 2/20 0.60
AKR1C1 Q04828 3/20 0.41
AKR1B10 O60218 1/20 0.41
AKR1C4 P17516 1/20 0.41
CYP2D6 P10635 1/20 0.38
AHR P35869 3/20 0.37
SCN9A Q15858 1/20 0.35
PGR P06401 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700240 0.81 SLC6A4 (0.42)
SCHEMBL20018243 0.81 APP (0.62) APPAKR1C3AKR1C2CYP2C19CYP3A4
SCHEMBL12050459 0.76 APP (0.63) APPAKR1C3AKR1C2CYP2C19CYP3A4
SCHEMBL28268518 0.75 SLC6A4 (0.47)
SCHEMBL407631 0.75 APP (1.00) APPAKR1C3AKR1C2CYP2C19CYP3A4
SCHEMBL29926966 0.75 APP (1.00) APPAKR1C3AKR1C2CYP2C19CYP3A4
SCHEMBL15307670 0.74 APP (0.79) APPAKR1C3AKR1C2CYP2C19CYP3A4
SCHEMBL1133859 0.73 APP (0.59) APPAKR1C3AKR1C2CYP2C19CYP3A4
SCHEMBL16321554 0.71 KDM1A (0.33) APPCYP2C19CYP3A4CYP2C9
SCHEMBL4093578 0.70 APP (0.68) APPAKR1C3AKR1C2CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015181094-A1 1-(2-FLUOROBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DOWN'S SYNDROME CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-03 WO disclosed
US-20150335596-A1 1-(2-FLUOROBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DOWN'S SYNDROME CHIESI FARMACEUTICI S.P.A. (IT) 2015-11-26 US disclosed
US-9056818-B2 Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-16 US disclosed
EP-2834214-A1 DERIVATIVES OF 1-(2-HALO-BIPHENYL-4-YL)- ALKANECARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Chiesi Farmaceutici S.p.A. (IT) 2015-02-11 EP disclosed
US-8835494-B2 Derivatives of 1-(2-halo-biphenyl-4-yl)-Alkanecarboxylic for the treatment of neurodegenerative diseases CHIESI FARMACEUTICI S.P.A. (IT) 2014-09-16 US disclosed
EP-2462098-B1 PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID CHIESI FARMA SPA (IT) 2013-10-23 EP disclosed
WO-2013150072-A1 DERIVATIVES OF 1-(2-HALO-BIPHENYL-4-YL)- ALKANECARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CHIESI FARMACEUTICI S.P.A. (IT) 2013-10-10 WO disclosed
US-20130267592-A1 DERIVATIVES OF 1-(2-HALO-BIPHENYL-4-YL)-ALKANECARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CHIESI FARMACEUTICI S.P.A. (IT) 2013-10-10 US disclosed
EP-2462098-A2 PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID Chiesi Farmaceutici S.p.A. (IT) 2012-06-13 EP disclosed
US-8076505-B2 Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid CHIESI FARMACEUTICI S.P.A. (IT) 2011-12-13 US disclosed
EP-2285765-A1 PROCESS OF PREPARING DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID CHIESI FARMACEUTICI S.p.A. (IT) 2011-02-23 EP disclosed
WO-2009149797-A1 PROCESS OF PREPARING DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID CHIESI FARMACEUTICI S.P.A. (IT) 2009-12-17 WO disclosed
US-20090312426-A1 PROCESS OF PREPARING DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID CHIESI FARMACEUTICI S.P.A. (IT) 2009-12-17 US disclosed
EP-2133322-A1 Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid CHIESI FARMACEUTICI S.p.A. (IT) 2009-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335596-A1 1-(2-FLUOROBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DOWN'S SYNDROME CALM1, IQGAP1, FKBP4 APP 755/4885AKR1C3 1699/4885AKR1C2 1216/4885
US-20090312426-A1 PROCESS OF PREPARING DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID CYP51A1, DHPS, CYP8B1 APP 4370/4885AKR1C3 161/4885AKR1C2 170/4885
US-20130267592-A1 DERIVATIVES OF 1-(2-HALO-BIPHENYL-4-YL)-ALKANECARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, PSEN1, PSEN2 APP 6/4885AKR1C3 712/4885AKR1C2 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.